Navigation Links
Folate receptors may serve as a front door to ovarian cancer treatment
Date:10/28/2011

AUGUSTA, Ga. A new strategy that takes advantage of ovarian cancer's reliance on folate appears to give relapse patients extra months of life with few side effects, researchers say.

The therapy uses the folate receptors on cancer cells as a sort of front door by pairing a substance attracted to the receptors with a chemotherapeutic agent too toxic to be given systemically, said Dr. Sharad Ghamande, Chief of the Section of Gynecologic Oncology at Georgia Health Sciences University.

Large numbers of folate receptors typically indicate the most aggressive ovarian cancers, as well as a variety of other cancers such as breast, lung and kidney.

The combination, called EC145, delivers a Vinca alkaloid directly inside cancer cells, improving effectiveness while reducing side effects particularly in women who overexpress folate receptors. A similar approach of pairing the folate ligand, which is attracted to the receptor, with a drug that makes those receptors glow, enables physicians to see how many folate receptors are present and who would be the best candidates for this treatment.

"We think this offers women with platinum-resistant disease a well-tolerated, effective treatment at a time when other drugs have failed them," Ghamande said. "We hope it will give them more quality time to meet important milestones, such as seeing a grandson graduate from high school." He noted that the strategy likely could enable targeted delivery of other drugs.

Ghamande is presenting findings of the phase 2 clinical trial at an Oct. 27-29 meeting in Brussels of the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Society of Clinical Oncology Annual Meeting on Molecular Markers in Cancer. The study enrolled 149 patients at 65 centers in North America and Poland; GHSU was among the top enrollers.

Platinum-based drugs are the standard of care for ovarian cancer, which is typically diagnosed in the late stages because there is no good screening test, such as the Pap smear for cervical cancer. After surgery and a round of chemotherapy, most women go into remission, but it's usually short-lived: about 70 percent of patients relapse within two years, Ghamande said. Physicians today often pair chemotherapeutic agents with biologic agents that bolster the immune response to try to improve outcomes. When women relapse or, inevitably, become platinum-resistant, they receive the chemotherapeutic agent Doxil.

The study compared, women receiving Doxil to those receiving Doxil as well as EC145. They found those with the most folate receptors on their cancer cells benefited the most from the new therapy: their progression-free survival went from 6.6 to 24 weeks, a 72 percent improvement from the standard therapy. "There is a proof of concept because the more folate receptors you overexpress, the better you do," Ghamande said.

Folate, or folic acid, is a B vitamin that is a basic component of cell metabolism and DNA synthesis and repair. Cancer cells, which are constantly multiplying and adapting, need more of it than healthy cells.

A larger Phase 3 study is underway internationally. The research was funded by Endocyte, Inc.


'/>"/>
Contact: Toni Baker
tbaker@georgiahealth.edu
706-721-4421
Georgia Health Sciences University
Source:Eurekalert  

Related medicine news :

1. High folate intake may reduce risk of colorectal cancer
2. Adding Folate to Tortilla Flour Might Cut Birth Defects Among Hispanics
3. Folate May Not Protect Against Premature Birth
4. Study finds that folate does not offer protection against preterm delivery
5. Hearing Loss in Elderly May Be Linked to Folate Deficiency
6. Nuclear receptors battle it out during metamorphosis in new fruit fly model
7. Historic first images of rod photoreceptors in the living human eye
8. Researchers get a grip on nervous systems receptors
9. Targeting nicotine receptors to treat cognitive impairments in schizophrenia
10. Nuclear receptors reveal possible interventions for cancer, obesity
11. New drug targets vitamin D receptors in hormone resistant prostate cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Folate receptors may serve as a front door to ovarian cancer treatment
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... in repaying their loans, more information about their loan terms and accounts, and ... student loan debt, including federal and private loans, has reached $1.3 trillion, with ...
(Date:4/29/2016)... ... 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group specializing ... their physicians has been invited to be a featured speaker at the Texas Society ... on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine and ...
(Date:4/29/2016)... Toronto, ON (PRWEB) , ... April 29, 2016 ... ... GlutenFreeCoupons.ca and the Canadian Celiac Association (CCA), is pleased to announce the launch ... about gluten-free products, nutritional articles, recipes, and more. The purpose of the ...
(Date:4/29/2016)... ... 2016 , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., ... and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. ... newly patented safety device secured by nasal surgeons onto the floor of the nasal ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Global  urinalysis ... billion by 2022, according to a new report ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... efficiency and accuracy delivered by the new generation ... novel urinalysis instruments and consumables. For instance, the ...
(Date:4/27/2016)... , April 27, 2016 ... announced the launch of a Phase 2 clinical study ... hearing in patients undergoing cochlear implantation (CI) surgery. This ... patients in Germany and ... the middle ear at the time of surgery. "Despite ...
(Date:4/26/2016)... 2016 Hill-Rom Holdings, Inc. (NYSE: HRC ... the Deutsche Bank 41 st Annual Health Care Conference ... You are invited to listen to the live discussion ... it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay of ... the live event and accessible at the links above until ...
Breaking Medicine Technology: